Investigational drug · Phase 2
TL-925
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Allergic Conjunctivitis, Allergic Conjunctivitis of Both Eyes.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
7
Any phase or sponsor naming "TL-925"
First trial start
2024
Oct 3, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TL-925", any sponsor or status.
Conditions studied
As listed on its trial records.
- Allergic Conjunctivitis
- Allergic Conjunctivitis of Both Eyes
Approved drugs for the same conditions: Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "TL-925" as an intervention, largest first.
- A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye DiseasePivotal-lookingStatus unknown
Telios Pharma, Inc.Industry
NCT06225973 · 880 participants (planned) · Start Feb 6, 2024 · Primary completion Dec 2024
Drug: TL-925 · For: Dry Eye Disease
Sites: Phoenix, Arizona; Glendale, California; La Mesa, California · 18 sites in all
- A Study of TL-925 as a Treatment for Dry Eye DiseasePivotal-lookingCompleted
Telios Pharma, Inc.Industry
NCT05745064 · 107 participants · Start Feb 27, 2023 · Primary completion Jul 11, 2023
Drug: TL-925; Placebo · For: Dry Eye Disease
Sites: Newport Beach, California; Colorado Springs, Colorado; Indianapolis, Indiana · 4 sites in all
- TL-925 for the Treatment of Allergic ConjunctivitisPivotal-lookingNot yet recruiting
Telios Pharma, Inc.Industry
NCT07938632 · 100 participants (planned) · Start Dec 2026 · Primary completion Mar 2027
Drug: TL-925; Placebo · For: Allergic Conjunctivitis of Both Eyes
Sites: Andover, Massachusetts
Telios Pharma, Inc.Industry
NCT06293820 · 80 participants · Start Apr 11, 2024 · Primary completion May 21, 2024
Drug: TL-925; Placebo · For: Allergic Conjunctivitis
Sites: Andover, Massachusetts
Telios Pharma, Inc.Industry
NCT06153342 · 70 participants (planned) · Start Nov 2023 · Primary completion Jan 2024
Drug: TL-925; Placebo · For: Allergic Conjunctivitis
Sites: Andover, Massachusetts
Telios Pharma, Inc.Industry
NCT06686472 · 66 participants (planned) · Start Oct 3, 2024 · Primary completion Dec 10, 2024
Drug: TL-925; Placebo · For: Allergic Conjunctivitis
Sites: Memphis, Tennessee
Telios Pharma, Inc.Industry
NCT07220408 · 60 participants (planned) · Start Oct 23, 2025 · Primary completion Feb 2026
Drug: TL-925; Placebo · For: Allergic Conjunctivitis
Sites: Smyrna, Tennessee
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Allergic Conjunctivitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.